Search results
Vertex Selected to Join Oracle ISV Accelerator for SaaS Initiative
Morningstar· 12 hours agoVertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions and a member of Oracle PartnerNetwork (OPN), today ...
Brokers Set Expectations for Vertex Pharmaceuticals Incorporated’s Q3 2025 Earnings (NASDAQ:VRTX)
ETF DAILY NEWS· 22 hours agoVertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) – Equities research analysts at Zacks Research cut their Q3 2025 EPS estimates for shares of Vertex ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Downgraded to “Buy” at StockNews.com
ETF DAILY NEWS· 4 days agoUBS Group dropped their price target on Vertex Pharmaceuticals from $498.00 to $466.00 and set a buy rating on the stock in a research note on Wednesday. HC Wainwright boosted ...
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Zacks via Yahoo Finance· 2 days agoVertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem...
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Motley Fool via Yahoo Finance· 2 days agoVertex Pharmaceuticals (NASDAQ: VRTX) has long been known for its expertise in treating cystic...
Vertex 2024 - our best bits and some surprises
Creative Bloq via Yahoo News· 1 day agoVertex 2024; two men on a stage. Vertex 2024, our own live artist event held at London's Business Design Centre, has ended and as we look back on a...
Vertex, Inc. Announces Pricing of Upsized $300 Million Convertible Senior Notes Offering
Morningstar· 22 hours agoVertex, Inc. (NASDAQ: VERX) (“Vertex”), a leading global provider of indirect tax solutions, today announced the pricing of $300 million aggregate principal ...
Vertex has top orphan drug in the pipeline, as pharma eyes shiny obesity drugs: report
FierceBiotech· 20 hours agoVertex’s cystic fibrosis triple combo is poised to become the top selling orphan drug in terms of...
Vertex (NASDAQ:VERX) Given “Market Outperform” Rating at JMP Securities
ETF DAILY NEWS· 20 hours agoJMP Securities reaffirmed their market outperform rating on shares of Vertex (NASDAQ:VERX – Free Report) in a research report released on Tuesday morning, Benzinga reports ...
Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
Morningstar· 1 day agoVertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to bolster production of its cell therapies for type- ...